What the Approval of Sarepta’s Elevidys Treatment for Duchenne’s Muscular Dystrophy Foreshadows

Chris Miller on August 21, 2023

Back in mid-May, we provided our POV around the FDA ad comm’s narrow positive vote in favor of Sarepta’s gene therapy candidate for Duchenne Muscular Dystrophy (DMD). On June 22, the FDA approved Sarepta’s Elevidys for DMD.